Navigation Links
DVT Treatment Vacuums Away Blood Clots – Prevents Disabilit

A study presented today demonstrates that a new technique safely and effectively removes blood clots in the body faster, reducing// patient risk for pulmonary embolism and disability.

The interventional radiology treatment was also shown to have a positive impact on patients’ quality of life, relieving symptoms such as pain and swelling, as well as greatly improving their ability to be active. The “rapid lysis” technique combines a clot-dissolving drug with a clot removal device, thus improving the breaking up and dissolving of the clot, which is then vacuumed out of the vein and into the catheter, nonsurgically clearing away the deep vein thrombosis (DVT). Blood flow is restored throughout the leg, resolving symptoms. Patients in the study had extensive, large volume DVT that commonly ran the length of the leg from the ankle to the pelvis, and often into the vena cava. Although the body may eventually dissolve clots, in the time needed to do so, permanent damage to the vein may occur, causing permanent disability and pain. In addition, previous studies have shown that clots in the larger veins will rarely clear on their own. The research was presented today at the Society of Interventional Radiology’s 32nd Annual Scientific Meeting.

“The new combination technique offers a significant advancement in the treatment of DVT, often allowing the interventional radiologists to break up the clot in one treatment. It has worked on even the largest, most difficult clots and could become the new standard technique, potentially changing the way all DVT patients are treated,” says Mark J. Garcia, M.D., interventional radiologist at Christiana Care Health System, Wilmington, DE.

This treatment worked on the largest, most difficult clots, allowing resolution of DVT quickly and safely while restoring blood flow in the vein. The treatment can reduce the length of a hospital stay, thus reducing costs. The current standard catheter-directed thromb olysis treatment uses a clot-dissolving drug only and, although highly effective, can take two to four days to work. This increases the patients’ risk of bleeding as well as increasing their stay in the ICU. Although the catheter-directed thrombolysis technique has been available for about a decade, many DVT patients don’t receive it. Instead, many patients are treated with blood thinners alone which can help prevent a life threatening pulmonary embolism, but do not help dissolve the clot. Long-term studies show that fifty percent of people with leg DVT treated with blood thinners alone develop the sequela of DVT, known as post-thrombotic syndrome. Post-thrombotic syndrome is caused by a combination of damage to the vein valves, as well as blocked blood flow in the vein from residual thrombus (clot). This condition is characterized by chronic leg pain and swelling which can lead to skin thickening and ulceration.

“Post-thrombotic syndrome is a common complication of DVT that is under-recognized and potentially preventable if we are able to dissolve the clots early, before permanent damage to the vein occurs,” says Garcia. “If we treat these patients within 14 days of their onset of symptoms, we are very successful in clearing the clot. Because the treatment is more rapid, safe and effective, patients are more likely to receive it and prevention of permanent damage is more likely to occur.”

Source-Newsise
SRM
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... introducing the Aerolib Learning Management System: an On-demand E-learning system for Clinical ... and Hospital Administration that is based on Aerolib`s successful education methodology of ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... SF expansion and facility enhancement of their 503A compounding pharmacy located in Ocala, ... growing demand of physicians and patients throughout the United States for high-quality human ...
(Date:1/19/2017)... ... 2017 , ... This month, the CEO and Clinical Director of Sober Living ... center in Delray Beach, Florida has been changed from Sober Living Outpatient to ‘SLO ... Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of unnamed ...
(Date:1/19/2017)... ... 19, 2017 , ... WhoHaha , a digital media company dedicated to ... (AHA) to produce a three-part video series that uses humor to highlight ways to ... launch of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans ...
(Date:1/19/2017)... ... 2017 , ... Cosmetic Town, an online plastic surgery community, begins 2017 with ... easier for their readers to get the information they desire. The procedures are now ... techniques used on those particular areas. , “We are excited to streamline our listings ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , , Marks E-QURE , ... agreement, following similar agreements in Israel and ... 5 billion global market ... leader in medical devices for the treatment of advanced wound care, announced today ... in Colombia for the Company,s patented Bio-electrical Signal Therapy ...
(Date:1/19/2017)... Jan. 18, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
Breaking Medicine Technology: